Vol 92, No 9 (2021)
Research paper
Published online: 2021-04-12

open access

Page views 1065
Article views/downloads 958
Get Citation

Connect on Social Media

Connect on Social Media

Factors affecting the choice of drospirenone as the component of combined contraceptive pill in daily clinical practice: the results of nation-wide survey

Magdalena Olszanecka-Glinianowicz1, Violetta Skrzypulec-Plinta2
Pubmed: 33844254
Ginekol Pol 2021;92(9):611-616.


Objectives: The aim of the multicenter, open-label, post-marketing, observational survey was to assess doctors’ preferences in choosing the progestogen component of the combined contraceptive pill (CCP) and factors affecting this choice in daily clinical practice as well as non-contraceptive reasons use of CCP containing drospirenone (CCPD) and patients’ tolerance and satisfaction with the treatment.
Material and methods: This multicenter, open-label, post-marketing, survey was performed nation-wide with the participation of 222 doctors involving and 10,345 patients treated with CCPD. The study questionnaire included questions concerning factors affecting the choice of drospirenone as a component of CCP and assessing prescription pattern of the drug as well as tolerance and satisfaction with the use of CCPD.
Results: The doctors frequently declared their choice of drospirenone as the progestogen component of CCP. The most important factors affecting the choice of drospirenone, declared by doctors, were tolerance level, consistent regulation of menstrual cycle and not causing spotting. CCPD was prescribed to patients with irregular menstrual cycles (62.7%) and painful menstruation (46.8%). During follow-up, significantly increased percentage of patients assessed the tolerance of treatment with CCPD as very good (52.5% vs 68.0%; p < 0.01) and very satisfied with its use (61.9% vs 77.8%, p < 0.01).
Conclusions: 1) Drospirenone is frequently chosen progestogen component in CCP by Polish gynecologists due to its good tolerance, consistent regulation of the menstrual cycle and no spotting in patients opinion. 2) CCPD was most frequently used in patients with irregular menstrual cycles and painful menstruation. 3) The patients were satisfied with the use CCPD and treatment was well tolerated.

Article available in PDF format

View PDF Download PDF file


  1. Rekomendacje Polskiego Towarzystwa Ginekologicznego dotyczące antykoncepcji hormonalnej – stan na rok 2006. Ginekologia po Dyplomie. 2006: 27–31.
  2. World Health Organization Contraception in adolescence. World Health Organization Library Cataloguing-in-Publication Data, Geneva 2004.
  3. French RS, Cowan FM. Contraception for adolescents. Best Pract Res Clin Obstet Gynaecol. 2009; 23(2): 233–247.
  4. Azziz R, Carmina E. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society Guideline. Position statement. J Clin Endocrinol Metab. 2006; 91(11): 4237–4245.
  5. Burkman R, Schlesselman J, Zieman M. Safety concerns and health benefits associated with oral contraception. American Journal of Obstetrics and Gynecology. 2004; 190(4): S5–S22.
  6. Pertyński T, Stachowiak G. Niskodawkowa, dwuskładnikowa doustna antykoncepcja u kobiet w okresie pre- i okołomenopauzalnym. Przegląd Menopauz. 2006; 4: 257–264.
  7. Rosenberg L, Palmer JR, Zauber AG, et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol. 1994; 139(7): 654–661.
  8. White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. Am J Obstet Gynecol. 2005; 192(6): 2055–2059.
  9. Simoncini T, Genazzani AR. A review of the cardiovascular and breast actions of drospirenone in preclinical studies. Climacteric. 2009; 13(1): 22–33.
  10. Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception. 2010; 82(5): 410–417.
  11. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000; 62(1): 29–38.
  12. Kelly S, Davies E, Fearns S, et al. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study. Clin Drug Investig. 2010; 30(5): 325–336.
  13. Kriplani A, Periyasamy AJ, Agarwal N, et al. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception. 2010; 82(2): 139–146.
  14. Marr J, Heinemann K, Kunz M, et al. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int J Gynaecol Obstet. 2011; 113(2): 103–107.
  15. Jaisamrarn U, Santibenchakul S. A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. Contracept Reprod Med. 2018; 3: 5.
  16. Cea-Soriano L, Wallander MA, García Rodríguez LA. Prescribing patterns of combined hormonal products containing cyproterone acetate, levonorgestrel and drospirenone in the UK. J Fam Plann Reprod Health Care. 2016; 42(4): 247–254.
  17. Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 2008; 77(4): 249–256.
  18. Al-Jefout M, Nawaiseh N. Continuous Norethisterone Acetate versus Cyclical Drospirenone 3 mg/Ethinyl Estradiol 20 μg for the Management of Primary Dysmenorrhea in Young Adult Women. J Pediatr Adolesc Gynecol. 2016; 29(2): 143–147.
  19. Boschitsch E, Skarabis H, Wuttke W, et al. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Eur J Contracept Reprod Health Care. 2000; 5 Suppl 3: 34–40.
  20. Dickerson V. Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone. J Reprod Med. 2002; 47(11 Suppl): 985–993.